Trial
NCT04491084
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Albert Einstein College of Medicine
Collaborators
Celldex Therapeutics
Condition
Non Small Cell Lung Cancer
Intervention
FLT3 Ligand (CDX-301)
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-28